Parasite | Eso | Sto | Cancer | ESD
[´ÜÀÏ ¹Ì¶õ. Single erosion] - End of document
´ÜÀÏ ¹Ì¶õ (single erosion)¿¡ ´ëÇؼ´Â Áß¿äÇÑ µÎ °¡Áö À̽´°¡ ÀÖ½À´Ï´Ù. (1) ´ÜÀÏ ¹Ì¶õÀ» À§±Ë¾çÀ¸·Î °úÀÎÁø´ÜµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Overmedication À̽´ÀÔ´Ï´Ù. (2) ´ÜÀÏ ¹Ì¶õ Áß ÀϺδ neoplastic processÀÔ´Ï´Ù. À§¾ÏÀÎ °æ¿ì°¡ ÀÖ´Ù´Â ¸»¾¸ÀÔ´Ï´Ù. Underdiagnosis À̽´ÀÔ´Ï´Ù. Á¶½ÉÇÏ°í ¶Ç Á¶½ÉÇÒ ÀÏÀÔ´Ï´Ù.
3. ¹Ì¶õÀÇ º´¸®
5. ¸î °³ÀÇ ¹Ì¶õµé oligo-erosions
6. ¾ÏÀ̳ª dysplasia·Î È®ÀÎµÈ ¹Ì¶õ Áõ·Ê
8. FAQs
9. References
1. À§±Ë¾çÀÌ ¾Æ´Ñµ¥ (= ¹Ì¶õ °°Àºµ¥) À§±Ë¾çÀ̶ó°í °úÀ×Áø´ÜµÇ´Â ÀÌÀ¯
1) Helicobacter Á¦±ÕÄ¡·á¸¦ À§ÇÏ¿©
2017³â±îÁö´Â À§±Ë¾ç¿¡¼´Â Á¦±ÕÄ¡·á¸¦ ÇÒ ¼ö ÀÖ°í, ¹Ì¶õ¿¡¼´Â Á¦±ÕÄ¡·á¸¦ ÇÒ ¼ö ¾ø½À´Ï´Ù. 2018³â 1¿ùºÎÅÍ´Â À§±Ë¾ç¿¡¼´Â ÀÏ¹Ý º¸Çè ±Þ¿©·Î, À§¿°¿¡¼´Â 100/100 (¾à°ª Àü¾× º»ÀÎ ºÎ´ã)À¸·Î Ä¡·áÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.
2) ȯÀÚ¿¡°Ô ¼³¸íÇϱâ À§ÇÏ¿©
'¹Ì¶õ'Àº ³Ê¹« ¾î·Æ½À´Ï´Ù. ȯÀÚ´Â °¨À» ÀâÀ» ¼ö ¾ø½À´Ï´Ù. '±Ë¾ç'Àº ´ë° ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼ú¸Ô°í ¼Ó¾²¸± ¶§ '±Ë¾ç Áõ¼¼'¶ó°í µé¾ú´ø ±â¾ïÀÌ ³¯Å״ϱî¿ä. ±Ë¾çÀ̶ó°í Çϸé "¾Æ, ±×·¡¼ ¹è°¡ ¾ÆÇ °ÍÀ̱¸³ª" Á¤µµ·Î ½±°Ô ¹Þ¾Æµé¿©Áý´Ï´Ù. ¹Ì¶õÀ̶ó°í Çϸé "±×°Ô ¹ºµ¥? ¾î¼¶ó°í?"¿Í °°Àº ¹ÝÀÀÀÌ ³ª¿Ã ¼ö ÀÖ½À´Ï´Ù. ±Ë¾ç¶§¹®¿¡ ¾ÆÇ °æ¿ì´Â ±Ë¾çÀ̶ó°í Áø´ÜÇÏ´Â °ÍÀÌ ¸Â½À´Ï´Ù. ±Ë¾çÀÌ ¾Æ´Ñµ¥µµ ´ÜÁö ¼³¸í¶§¹®¿¡ '±Ë¾ç' Áø´ÜÀ» ºÙÀÌ´Â °ÍÀº À߸øÀÔ´Ï´Ù. °üÇàÀÌÁö¸¸ À߸øÀÔ´Ï´Ù. Functional dyspepsia¸¦ Àß ¼³¸íÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀÌ ÇÊ¿äÇÕ´Ï´Ù.
3) À߸øµÈ ¿¬±¸ µðÀÚÀÎ ¶§¹®¿¡
AspirinÀ̳ª NSAID¸¦ º¹¿ëÇÏ´Â »ç¶÷Àº ±Ë¾çÀÌ Àß »ý±é´Ï´Ù. NSAIDÀÇ °æ¿ì 1³â¿¡ Æò±Õ 1% Á¤µµ ÃâÇ÷¼º ±Ë¾çÀÌ ¹ß»ýÇÕ´Ï´Ù. ÃâÇ÷À» µ¿¹ÝÇÏÁö ¾Ê´Â ±Ë¾çÀº À̺¸´Ù ¸¹½À´Ï´Ù. ¹Ì¶õÀº ÈξÀ ´õ ¸¹½À´Ï´Ù. AspirinÀ̳ª NSAID¿¡ ÀÇÇÑ À§Àå°ü ¼Õ»óÀ» ¿¹¹æÇÏ´Â ¾à¿¡ ´ëÇÑ ¿¬±¸¿¡¼ 3 mm ÀÌ»óÀÇ mucosal defect¸¦ ±Ë¾çÀ¸·Î Á¤ÀÇÇÑ °æ¿ì°¡ ÀÖ½À´Ï´Ù. ¸»µµ µÇÁö ¾Ê½À´Ï´Ù. ´ÜÁö ¿¬±¸ ÆíÀǸ¦ À§ÇÏ¿©, ȤÀº positive result¸¦ ³»¼ ¾àÀ» ¸¹ÀÌ Æȱâ À§ÇÏ¿© ±Ë¾çÀÌ ¾Æ´Ñ °ÍÀ» ±Ë¾çÀ̶ó ºÎ¸£´Â Ȳ´çÇÑ °æ¿ìÀÔ´Ï´Ù. ÀÌ·± ¼Ó»çÁ¤À» ¸ð¸£´Â ÀÇ»çµéÀÌ ¿¬±¸°á°ú¸¦ Àß ¸ø ÀÌÇØÇϱ⵵ ÇÕ´Ï´Ù. "À½. 3 mm°¡ ³ÑÀ¸¸é ±Ë¾çÀ̱º......" ¾Æ´Õ´Ï´Ù. õ¹ÚÇÑ ÀÚº»ÁÖÀÇ¿¡ ÀÇÇÑ À߸øµÈ ³¬½ÃÁúÀÏ »ÓÀÔ´Ï´Ù.
4) ¹è¿ìÁö ¸øÇؼ
³»½Ã°æ ¼Ò°ßÀ» ÃæºÐÈ÷ ¹è¿ìÁö ¸øÇÑ ÃʽÉÀÚÀÇ °æ¿ì ±Ë¾ç°ú ¹Ì¶õÀÇ Æ¯Â¡À» ¸ð¸¦ ¼ö ÀÖ½À´Ï´Ù. ¾î±ú³Ê¸Ó·Î ±³¼ö³ª ¼±¹è°¡ °á°ú¸¦ ³»´Â °ÍÀ» ¸î ¹ø º» °ÍÀÌ ÀüºÎÀÎ °æ¿ìÀÔ´Ï´Ù. ½º½º·Î °øºÎÇÏ´Â ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù.
2. À§±Ë¾çÀÌ ¾Æ´Ñµ¥ À§±Ë¾çÀ̶ó°í °úÀ×Áø´ÜÇÒ ¶§ ¹ß»ýÇÏ´Â ÀÏ
1) Helicobacter Á¦±ÕÄ¡·á¸¦ À§ÇÏ¿© °úÀ×Áø´ÜÀ» ÇÑ °æ¿ì
±Ë¾ç Àç¹ßÀ» À§ÇÏ¿© Ç×»ýÁ¦¸¦ µå·È´õ¶óµµ 75% Á¤µµ¸¸ Á¦±ÕµË´Ï´Ù. ¾ÏÀÌ ¾Æ´Ï¶ó´Â °ÍÀ» ¹àÈ÷±â À§ÇÏ¿©, ¶Ç Á¦±Õ È®ÀÎÀ» À§ÇÏ¿© ³»½Ã°æ °Ë»ç, Á¶Á÷°Ë»ç¸¦ ÇØ¾ß ÇÕ´Ï´Ù. ¸¸¾à Á¦±ÕÀÌ ¾È µÇ¾ú´Ù¸é ¶Ç ¾àÀ» ¸Ô°í ¶Ç °Ë»ç¸¦ ÇØ¾ß ÇÕ´Ï´Ù. À̸¦ È®ÀÎÇϱâ À§ÇÏ¿© ¶Ç °Ë»ç¸¦ ÇØ¾ß ÇÏ°í ¶Ç Á¦±ÕÀÌ ¾È µÇ¾ú´Ù¸é ¶Ç ¾àÀ» ¸Ô¾î¾ß µË´Ï´Ù. ¶Ç¶Ç¶Ç¶Ç¶Ç...... ²¿¸®¿¡ ²¿¸®¸¦ ¹°°í ºÒÇÊ¿äÇÑ ÀÇ·áÇàÀ§°¡ ÀÌ·ç¾îÁý´Ï´Ù. ³ª´Â º° ¹®Á¦°¡ ¾ø´Âµ¥ º´¿ø¿¡¼´Â ÀÚ²Ù "¾àÀ» ¸Ô¾î¶ó, °Ë»ç¸¦ Çضó"°í ÇÏ´Ï ÀÇ·áÀü¹Ý¿¡ ´ëÇÑ ½Å·Ú°¨ÀÌ ³·¾ÆÁú ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù.
2) ¼³¸íÀ» À§ÇÏ¿© °úÀ×Áø´ÜÀ» ÇÑ °æ¿ì
º¹ÅëÀÇ ¿øÀÎÀÌ ±Ë¾çÀ̾ú´Ù¸é ±Ë¾ç Ä¡·á ÈÄ Áõ»óÀÌ ÁÁ¾ÆÁ®¾ß ÇÕ´Ï´Ù. Functional dyspepsia¿¡¼ ±Ë¾çÄ¡·á¸¦ ÇÑµé º¹ÅëÀÌ ÁÁ¾ÆÁú ¸® ¾ø½À´Ï´Ù. "ÀÌ»óÇÏ´Ù. ±Ë¾çÄ¡·á¸¦ Çߴµ¥ ¿Ö °è¼Ó ¾ÆÇÁÁö?" ȯÀÚ´Â ´Ù¸¥ º´¿ø¿¡ °©´Ï´Ù. ±×·±µ¥ ±×°÷ ÀÇ»ç´Â óÀ½ºÎÅÍ ±Ë¾çÀÌ ¾Æ´Ï¾ú´Ù°í ¼³¸íÇÕ´Ï´Ù. ȯÀÚ´Â °¼¿ì¶×ÇÕ´Ï´Ù. "ÀÌ·± °³¶±°°Àº °æ¿ì°¡ ÀÖ³ª..." ½Å·Ú°¡ ¹«³ÊÁý´Ï´Ù.
3) À߸øµÈ ¿¬±¸ °á°ú¸¦ º¸°í °úÀ×Áø´ÜÀ» ÇÑ °æ¿ì
ºÒÇÊ¿äÇÑ Åõ¾àÀ» ÇÏ°Ô µË´Ï´Ù. ó¹æ À¯µµ ¸ñÀûÀ¸·Î µðÀÚÀÎµÇ¾î ½ÇÇàµÈ ¿¬±¸°¡ ÀûÁö ¾Ê½À´Ï´Ù. ¿¬±¸ °á°ú¸¦ Á¶½É½º·´°Ô Çؼ®ÇØ¾ß ÇÒ °ÍÀÔ´Ï´Ù.
4) ¹è¿ìÁö ¸øÇؼ °úÀ×Áø´ÜÀ» ÇÑ °æ¿ì
´ÙÇàÀÔ´Ï´Ù. Áö±ÝÀÌ¶óµµ Àß ¹è¿ö¼ ¾ÕÀ¸·Î ±Ë¾çÀ̶ó´Â Áø´ÜÀ» Àß ºÙÀÌ¸é µË´Ï´Ù. °¡Àå ¿¹ÈÄ°¡ ÁÁÀº °æ¿ìÀÔ´Ï´Ù.
5) ±âŸ
±Ë¾çÀÌ ¾Æ´Ñµ¥ ȯÀÚ°¡ ±Ë¾çÀ¸·Î Ä¡·áÇß´Ù°í ¾Ë°í ÀÖÀ¸¸é ¸Õ Èʳ¯ ÀÌ»óÇÑ ÀÏÀÌ ¹ú¾îÁú ¼ö ÀÖ½À´Ï´Ù. ´Ù¸¥ º´À¸·Î º´¿øÀ» ã¾ÒÀ» ¶§ history takingÀÌ ¾ûÅ͸®°¡ µË´Ï´Ù. ±×·Î ÀÎÇÑ ºÒÇÊ¿äÇÑ °Ë»ç³ª ºÒÇÊ¿äÇÑ Åõ¾àÀ» ¹Þ°Ô µË´Ï´Ù. º¸Çè¿¡ °¡ÀÔÇÒ ¶§ ±Ë¾ç º´·ÂÀÌ ÀÖÀ¸¸é ºÒÀÌÀÍÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¾Æ¸¶ ´Ù¸¥ ÀÌ»óÇÑ Àϵµ ¸¹À» °ÍÀÔ´Ï´Ù.
Á¶Á÷ÀÇ °á¼ÕÀÌ Á¡¸·Ãþ¿¡ ±¹ÇÑµÇ¸é ¹Ì¶õ, Á¡¸·Ãþ ¸ðµÎ°¡ Å»¶ôµÇ°í Á¡¸·ÇÏÃþ±îÁö Á¶Á÷ °á¼ÕÀÌ ÀÖÀ¸¸é ±Ë¾çÀ̶ó°í ¹è¿ü½À´Ï´Ù. ´õ ÁÁÀº º´¸®ÇÐÀû Á¤ÀǸ¦ º» ÀûÀÌ ¾ø½À´Ï´Ù.
4. ´ÜÀÏ ¹Ì¶õÀÇ ³»½Ã°æ ¼Ò°ß. Endoscopic findings of single erosion
¹Ì¶õÀÌ µü Çϳª¸é ¾ÏÀÏ ¼ö ÀÖÀ¸´Ï Á¶Á÷°Ë»ç¸¦ Ç϶ó°í ¹è¿ü½À´Ï´Ù. ±×³É erosionµµ ÀÖ°í elevated erosionµµ ÀÖ½À´Ï´Ù. ±×·±µ¥ ³»½Ã°æ¿¡¼ ¾Ïó·³ º¸ÀÎ ´ÜÀÏ ¹Ì¶õÀº ¾ÏÀ¸·Î ³ª¿À°í, º° °Í ¾Æ´Ñ °Íó·³ º¸ÀÎ ¹Ì¶õÀº º° °Í ¾Æ´Ñ °ÍÀ¸·Î ³ª¿É´Ï´Ù. ´ÜÀϹ̶õ °¨º°Áø´ÜÀÇ ÀûÁß·üÀ» ³ôÀÌ´Â °ÍÀÌ ³»½Ã°æ Àǻ翡°Ô´Â ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿¬½À¹Û¿¡ ¾ø½À´Ï´Ù. ÀÚÁÖ º¸°í ´À³¢´Â °ÍÀÌÁö¿ä. ¸ÕÀú º° °Í ¾Æ´Ñ ´ÜÀÏ ¹Ì¶õÀÇ ¿¹ÀÔ´Ï´Ù.
hematinÀ» µ¿¹ÝÇÑ erosionÀÌ¸é¼ ÁÖº¯ÀÌ ¹ßÀûµÇ¾î º¸À̸é Á¾¾ç¼ºÀÌ ¾Æ´Õ´Ï´Ù.
Ȥ½Ã ¾ÏÀÏ ¼öµµ ÀÖ°Ú´Ù´Â »ý°¢ÀÌ µé¾úÀ¸³ª Á¶Á÷°Ë»ç¿¡¼ À§¿°À¸·Î¸¸ ³ª¿À´Â °æ¿ìµµ ÀûÁö ¾Ê½À´Ï´Ù.
ù Á¶Á÷°Ë»ç¿¡¼ H. pylori À§¿°À¸·Î¸¸ ³ª¿Ô´Âµ¥ ¾Ö¸ÅÇÏ´Ù°í º¸°í ¼ö ÁÖ ÈÄ ´Ù½Ã °Ë»ç¸¦ ÇÏ¿´À¸³ª µ¿ÀÏ ¼Ò°ßÀ̾ú½À´Ï´Ù. ÀÌ °æ¿ì´Â Á¦±ÕÄ¡·á¸¦ ÇØ ÁÖ´Â °ÍÀÌ ÁÁÁö ¾ÊÀ»±î »ý°¢ÇÕ´Ï´Ù. Ä¡·á¸¦ À§Çؼ ȤÀº °¨º°Áø´ÜÀ» À§Çؼ... ±×·¯³ª ±ÔÁ¤ À§¹ÝÀÌ´Ï °í¹ÎÇÏÁö ¾ÊÀ» ¼ö ¾ø½À´Ï´Ù. (1) »è°¨À» ´çÇÏ´õ¶óµµ Ä¡·áÇÒ °ÍÀΰ¡, (2) »è°¨À» ÇÇÇϱâ À§ÇÏ¿© ±Ë¾çÀ̶ó´Â °ÅÁþ Áø´ÜÀ» ºÙÀÌ°í Ä¡·áÇÒ °ÍÀΰ¡, (3) ±ÔÁ¤¿¡ µû¶ó °æ°ú°üÂû¸¸ ÇÒ °ÍÀΰ¡? ¿©·¯ºÐÀº ¾î¶»°Ô ÇÏ°Ú½À´Ï±î?
[2014-9-24. ¾Öµ¶ÀÚ Áú¹®]
±ÝÀÏ ³»¿ëÁß 5¹ø ´ÜÀϹ̶õ ´Ü¶ô¿¡¼ 4¹ø° slide Áï H. pylori À§¿°À¸·Î 2¹ø Á¶Á÷°Ë»ç¸¦ Çϼ̴ٴ ȯÀÚ¿¡ ´ëÇؼÀÔ´Ï´Ù. À§³»½Ã°æ»ó º¸ÀÌ´Â erosive lesionÀÇ ¾ç»óÀÌ Á¦ ¼Ò°ßÀ¸·Ð EGC IIc¸ð¾ç°ú ¾ÆÁÖ À¯»çÇÏ°Ô º¸ÀÔ´Ï´Ù. 2¹øÀÇ Á¶Á÷°Ë»ç¿¡¼ ¿°ÁõÀ¸·Î ³ª¿Í¼ ¾ÏÀÇ °¡´É¼ºÀº È®½ÇÈ÷ ¹èÁ¦ÇϽŠ°Ç°¡¿ä? ÀÌ Áõ·Ê¿¡¼ óÀ½ Á¶Á÷°Ë»ç Àü À°¾ÈÀ¸·Î ¾Ï °¡´É¼ºÀº ¸î %Á¤µµ·Î º¸¼Ì³ª¿ä?
[2014-9-26. ÀÌÁØÇà ´äº¯]
9³â Àü ȯÀÚ¿´½À´Ï´Ù. Àǹ«±â·ÏÀ» ´Ù½Ã È®ÀÎÇØ º¸¾Ò½À´Ï´Ù. Á¦ ȯÀÚ´Â ¾Æ´Ï°í Á¦°¡ consult¸¦ ¹Þ¾Ò´ø ºÐÀ̾ú½À´Ï´Ù. ±â·Ï¿¡ µû¸£¸é "º¸ÇèÀº Àû¿ëµÇÁö ¾ÊÁö¸¸ H. pylori Á¦±ÕÄ¡·á ±ÇÀ¯"ÇÏ¿´°í ÀÌÈÄ ÃßÀû°üÂûÀº ¾È µÇ¾î ÀÖ¾ú½À´Ï´Ù. µû¶ó¼ Àå±âÀûÀ¸·Î °á°ú´Â ¾î¶»°Ô µÇ¾ú´ÂÁö ÇöÀç·Î¼´Â ¾Ë ¼ö ¾ø½À´Ï´Ù. Çѹø Á¤µµ ´õ Á¶Á÷°Ë»ç·Î È®ÀÎÇÏ°íÀÚ ÇÏ¿´´Âµ¥ ȯÀÚ°¡ º´¿øÀ» ãÁö ¾ÊÀ¸¼Å¼ ÃÖÁ¾ °á·ÐÀº ¾ø½À´Ï´Ù.
Áú¹®À» Áּż »çÁøÀ» ´Ù½Ã º¸¾Ò½À´Ï´Ù. ¾Ï °¡´É¼ºÀº 50-60% Á¤µµ·Î ÆǴܵ˴ϴÙ. ¹°·Ð ÇÔ¸ôÇü ¼±Á¾ÀÏ °¡´É¼ºµµ ÀÖ½À´Ï´Ù. ±×·±µ¥ ÀÌ·± ŸÀÔÀÇ ¾à°£ ÇÔ¸ôµÈ º´¼Ò´Â Á¤È®È÷ target biopsy°¡ µÇ¸é Á¶Á÷°Ë»çÀÇ ½Å·Úµµ´Â ³ô´Ù°í ÇÒ ¼ö ÀÖ½À´Ï´Ù.
Áú¹®¿¡ ´äÇÏÀÚ¸é... ÀÚ·á´Â ¾øÁö¸¸ °æÇè»ó EGCÀÇ Á¶Á÷°Ë»ç Á¤È®µµ´Â ÃÖ¼ÒÇÑ 80-90% ÀÌ»óÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. Á¶Á÷°Ë»ç¿¡¼ µÎ ¹ø ¾ÏÀÌ ¾Æ´Ï¸é 95-98% ÀÌ»ó ¾ÏÀÌ ¾Æ´Ñ °ÍÀÔ´Ï´Ù. ±×·¯³ª ÃßÀû°Ë»ç´Â ÇÊ¿äÇÕ´Ï´Ù. ÇÑ ¹ø Á¤µµ ´õ Çغ¸°í ½Í¾úÁö¸¸ ¸øÇÑ °ÍÀº ¸ø³» ¾Æ½±½À´Ï´Ù. ±×·¯³ª ¿ÀÁö ¾Ê´Â ȯÀÚ¸¦ °Á¦·Î ¿À°Ô ÇÒ ¹æ¹ýµµ ¸¶¶¥Ä¡ ¾Ê½À´Ï´Ù. °ú°Å¿¡´Â ȯÀÚ¿¡°Ô ÀüÈÇÏ¿© Á¦ ÀÇ°ßÀ» °¿äÇÑ Àûµµ ÀÖ¾úÁö¸¸ ¸î ¹ø Å©°Ô ´çÇÏ°í ³ Èķδ ÀÌ·¸°Ô »ý°¢ÇÕ´Ï´Ù. ¿À´Â ȯÀÚ ¸·Áö ¸»°í °¡´Â ȯÀÚ ÀâÁö ¸»ÀÚ. ¸Å¿ì »ó¼¼È÷ ¼³¸íÇÏ°í ±× ÀÌÈķδ ȯÀÚÀÇ ¼±ÅÃÀ» µû¸¦ ¼ö ¹Û¿¡ ¾ø´Ù´Â °ÍÀÌ ÇöÀç ÀÇ·áȯ°æÀÇ ÇÑ°èÀÔ´Ï´Ù.
5. ¸î °³ÀÇ ¹Ì¶õµé. oligo-erosions
¹Ì¶õÀÌ ÀÖ±â´Â Çѵ¥ À§¿¡¼ º¸¿©µå¸° ¹Ì¶õ¼º À§¿°°ú °°ÀÌ ¹«¼öÈ÷ ¸¹Àº Á¤µµ°¡ ¾Æ´Ñ ¿¹°¡ ¸¹½À´Ï´Ù. ¸î °³ÀÇ ¹Ì¶õµéÀÎ °ÍÀÌÁö¿ä. ÀÌ ¶ÇÇÑ ±×³É ¹Ì¶õ¼º À§¿°À¸·Î ºÎ¸£´Â °ÍÀÌ ÁÁ½À´Ï´Ù. ±¸ºÐÇϱâ À§ÇÏ¿© oligo-erosions¶ó´Â Á¦ ³ª¸§ÀÇ ¿ë¾î¸¦ ¸¸µé¾ú½À´Ï´Ù. °ÇÁø¿¡¼ ±Ë¾çÀ̶ó°í ȤÀº r/o EGC·Î ÀǷڵǴ °æ¿ì°¡ ¸¹±â ¶§¹®ÀÔ´Ï´Ù.
°ÇÁø¿¡¼ ±Ë¾çÀ̶ó°í ÀÇ·ÚµÈ ºÐÀÔ´Ï´Ù. ÀÌ Á¤µµ¸¦ ±Ë¾çÀ̶ó°í ºÎ¸¦ ¼ö´Â ¾ø½À´Ï´Ù.
°ÇÁø¿¡¼ ±Ë¾çÀ̶ó°í ÀÇ·ÚµÈ ºÐÀÔ´Ï´Ù. À§ Áõ·Êº¸´Ù´Â ´Ù¼Ò Å©Áö¸¸ ±×·¡µµ ÀÌ Á¤µµ¸¦ ±Ë¾çÀ̶ó°í ºÎ¸¦ ¼ö ¾ø´Ù°í »ý°¢ÇÕ´Ï´Ù. ´ç¿¬È÷ Áõ»óÀº ¾ø¾ú½À´Ï´Ù.
6. ¾ÏÀ̳ª dysplasia·Î È®ÀÎµÈ ¹Ì¶õ Áõ·Ê
°¡±îÀÌ À§Ä¡ÇÑ µÎ °³ÀÇ Àúµµ ¼±Á¾
ù Á¶Á÷°Ë»ç¿¡¼ ¾ÏÀ¸·Î ³ª¿ÀÁö ¾Ê¾Æ Àç°ËÇÏ¿© ¾ÏÀ¸·Î Áø´ÜÇÏ°í ³»½Ã°æÄ¡·á
°Ë»çÀÚ´Â erosion, r/o EGC, less likely·Î ÁÖ¾úÀ¸³ª Á¶Á÷°Ë»ç¿¡¼ ¾ÏÀ¸·Î ³ª¿È
(2012) ¸î ³â ÈÄ °°Àº À§Ä¡ÀÇ Á¶Á÷°Ë»ç¿¡¼ À§¾ÏÀÌ È®ÀεǾî ÀǷڵǽŠºÐÀ¸·Î ESD·Î Ä¡·áÇÏ¿´½À´Ï´Ù.
ESD: Early gastric carcinoma
1. Location : antrum, postero-greater curvature
2. Gross type : EGC type IIc
3. Histologic type : tubular adenocarcinoma, well differentiated
4. Histologic type by Lauren : intestinal
5. Size of carcinoma : (1) longest diameter, 14 mm (2) vertical diameter, 9 mm
6. Depth of invasion : invades mucosa (muscularis mucosa) (pT1a)
7. Resection margin : free from carcinoma(N) safety margin : distal 12 mm, proximal 7 mm, anterior 12 mm, posterior 14 mm, deep 300 §
8. Lymphatic invasion : not identified(N)
9. Venous invasion : not identified(N)
10. Perineural invasion : not identified(N)
11. Microscopic ulcer : absent
12. Histologic heterogeneity: absent(2015) 60´ë Áß¹Ý ¿©¼ºÀ̾ú½À´Ï´Ù. Single erosionÀ¸·Î forceps biopsy¿¡¼ adenoma with HGD·Î ³ª¿Í ÀǷڵǾú½À´Ï´Ù. ESD¸¦ ÇÏ¿´°í ¾ÏÀ¸·Î ³ª¿Ô½À´Ï´Ù. Single erosionÀº ´Ã Á¾¾ç¼º ÁúȯÀÇ °¡´É¼ºÀ» °í·ÁÇØ¾ß ÇÕ´Ï´Ù.
ESD: Early gastric carcinoma
1. Location : proximal antrum, anterior wall
2. Gross type : EGC type IIc
3. Histologic type : tubular adenocarcinoma, well differentiated
4. Histologic type by Lauren : intestinal
5. Size of carcinoma : (1) longest diameter, 6 mm (2) vertical diameter, 4 mm
6. Depth of invasion : invades mucosa (lamina propria) (pT1a)
7. Resection margin : free from carcinoma(N); safety margin : distal 7 mm, proximal 8 mm, anterior 10 mm, posterior 10 mm, deep 1800 §
8. Lymphatic invasion : not identified(N)
9. Venous invasion : not identified(N)
10. Perineural invasion : not identified(N)
11. Microscopic ulcer : absent
12. Histologic heterogeneity: absentÁ¶Á÷°Ë»ç¿¡¼ atypical gland with HGD·Î ³ª¿Í ÀǷڵǾú°í ESD ÈÄ ¾ÏÀ¸·Î È®ÀÎÇÔ.
ESD: Early gastric carcinoma
1. Location : antrum, posterior wall
2. Gross type : EGC type IIb
3. Histologic type : tubular adenocarcinoma, moderately differentiated
4. Histologic type by Lauren : intestinal
5. Size of carcinoma : (1) longest diameter, 4 mm (2) vertical diameter, 2 mm
6. Depth of invasion : invades mucosa (lamina propria) (pT1a)
7. Resection margin : negative
8. Lymphatic invasion : not identified(N)
9. Venous invasion : not identified(N)
10. Perineural invasion : not identified(N)
11. Microscopic ulcer : absent
12. Histologic heterogeneity: absent
Tubular adenoma with high grade dysplasia
1. Location : antrum, posterior wall
2. Gross type : flat
3. Size of adenoma : (1) longest diameter, 4 mm (2) vertical diameter, 3 mm
4. Resection margin : negative resection margins(N)
ÀÌ Áõ·Ê¿¡ ´ëÇÑ »ó¼¼ÇÑ Çؼ³Àº ¿©±â¸¦ Âü°íÇϼ¼¿ä.(2017, F/60)
Stomach, ESD: Early gastric carcinoma
1. Location : antrum, lesser curvature
2. Gross type : EGC type IIc
3. Histologic type : tubular adenocarcinoma, moderately differentiated
4. Histologic type by Lauren : intestinal
5. Size of carcinoma : (1) longest diameter, 10 mm (2) vertical diameter, 6 mm
6. Depth of invasion : invades mucosa (muscularis mucosa) (pT1a)
7. Resection margin : free from carcinoma(N) safety margin : distal 15 mm, proximal 11 mm, anterior 18 mm, posterior 20 mm, deep 150 §
8. Lymphatic invasion : not identified(N)
9. Venous invasion : not identified(N)
10. Perineural invasion : not identified(N)
11. Microscopic ulcer : absent
12. Histologic heterogeneity: absentSingle erosionÀº ¾ÏÀÏ ¼ö ÀÖ½À´Ï´Ù. Á¶Á÷°Ë»ç µü ÇÑ Á¡ ½ÃÇàÇÏ¿´°í "atypical glands, suspected tubular adenocarcinoma°¡ ³ª¿Ô½À´Ï´Ù. ¾ÏÀ̶ó°í ÆǴܵǾú°í ESD¸¦ Çß½À´Ï´Ù.
Stomach, ESD: Early gastric carcinoma
1. Location : antrum, anterior wall
2. Gross type : EGC type IIc
3. Histologic type : tubular adenocarcinoma, moderately differentiated
4. Histologic type by Lauren : intestinal
5. Size of carcinoma : (1) longest diameter, 6 mm (2) vertical diameter, 3 mm
6. Depth of invasion : invades mucosa (muscularis mucosa) (pT1a)
7. Resection margin : free from carcinoma(N), safety margin : distal 14 mm, proximal 13 mm, anterior 14 mm, posterior 14 mm, deep 500 §
8. Lymphatic invasion : not identified(N)
9. Venous invasion : not identified(N)
10. Perineural invasion : not identified(N)
11. Microscopic ulcer : absent
12. Histologic heterogeneity: absent
Aspirin º¹¿ëÀÚ°¡ »óº¹ºÎ ºÒÆí°¨À¸·Î ³»½Ã°æÀ» Çß½À´Ï´Ù. Stroke º´·ÂÀÌ ÀÖ´Â DM nephropathy ȯÀÚ·Î aspirinÀº ²÷±â ¾î·Á¿î »óȲÀ̾ú½À´Ï´Ù. ¿©·¯ºÐÀº ¾î¶»°Ô ±â¼úÇÏ°í ¾î¶»°Ô Áø´ÜÇÏ°í ¾î¶»°Ô °ü¸®ÇÏ°Ú½À´Ï±î?
[2014-9-24. ¾Öµ¶ÀÚ 1 ´äº¯]
Prepylorus area¿¡ multiple erosionÀÌ °üÂûµÇ¸ç, erosive gastritis·Î assessÇÏ°í aspirinÀ» ²÷±â ¾î·Æ´Ù¸é PPI¸¦ ó¹æÇÏ°í ÃßÀû°üÂûÇÏ°Ú½À´Ï´Ù.
[2014-9-24. ¾Öµ¶ÀÚ 2 ´äº¯]
Àú´Â 2Â÷º´¿ø¿¡¼ °ÇÁø³»½Ã°æÀ» ÇÏ°í Àִµ¥¿ä, ±³¼ö´ÔÀÇ EndoTODAY¸¦ Á¢ÇÏ¸é¼ Ã¥¿¡ ³ª¿ÀÁö ¾Ê´Â ºÎºÐµé¿¡ ´ëÇØ ¸¹Àº °ÍÀ» ¹è¿ì°Ô µÇ¾ú½À´Ï´Ù. "¹Ì¶õ"°ú "±Ë¾ç"¿¡ ºÎºÐ¿¡ ´ëÇؼ´Â ¸¹Àº µµ¿òÀÌ µÇ¾ú½À´Ï´Ù. °¨»çÇÕ´Ï´Ù. Áú¹®ÇϽŠ³»½Ã°æ ¼Ò°ßÀº ƯÈ÷ Æǵ¶°ú f/u¿¡ ´ëÇؼ °¡Àå °ïȤ½º·¯¿öÇÏ´Â °Íµé Áß ÇϳªÀÔ´Ï´Ù. ¿ì¼± Á¦°¡ ±â¼úÇÏ´Â ÇÏ´Â ¹æ½ÄÀ¸·Î Àû¾îµå¸®°Ú½À´Ï´Ù..
񃬣: multiple erosive changed mucosa was noted on antrum, Bx#1x1 was done at raised erosion on LC of antrum
Áø´Ü: erosive gastritis
°èȹ: planÀ¸·Î PPI + mucoprotective + prokinetics x14 ó¹æ ÈÄ ¾à ¼ÒÁø½Ã¿¡ ¿Ü·¡ f/uÇÏ¿© Á¶Á÷°Ë»ç»ó H.pylori(+)À̸é Á¦±ÕÄ¡·á¸¦ ±ÇÇÏ°í ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ À§ º´º¯À» "À§±Ë¾ç"À¸·Î °í·ÁÇÏ¿© ¾à¹°º¹¿ë±â°£À» 6~8ÁÖ·Î ÇÒÁö¿¡ ´ëÇؼ´Â ¾ÆÁ÷±îÁö rationale°¡ ¾ø½À´Ï´Ù. ¼ÖÁ÷È÷ ÀúÈñº´¿ø ¼Òȱ⠳»°ú staffºÐµé°úµµ À§¿Í°°Àº ¼Ò°ß¿¡ ´ëÇؼ ¸¹Àº À̾߱⸦ ³ª´©¾ú´Âµ¥, ¾î¶² ºÐÀº CLO¸¦ À§Çؼ shallow ulcer·Î ±â¼úÇϽðí, À§±Ë¾çÀ¸·Î 8ÁÖÁ¤µµ ¾à¹° º¹¿ë½ÃŲ ÈÄ ÃßÀû³»½Ã°æÀ» ÇÏ°í ÀÖ½À´Ï´Ù.
[2014-9-24. ¾Öµ¶ÀÚ 3 ´äº¯]
񃬣 : multiple raised and flat erosive inflammations on antrum
Áø´Ü : Erosive gastritis
°ü¸® : cimetidine°ú almagelÀ» ó¹æÇÏ°Ú½À´Ï´Ù.
[2014-9-25. ¾Öµ¶ÀÚ 4 ´äº¯]
±â¼ú : ´Ù¹ß¼º ¹Ì¶õµéÀÌ ÀüÁ¤ºÎ¿¡¼ °üÂûµÊ.
Áø´Ü: ¾Æ½ºÇǸ°¿¡ ÀÇÇÑ ¹Ì¶õ¼º À§¿°.
°ü¸® : 2ÁÖÁ¤µµ Ä¡·áÇÏ°Ú½À´Ï´Ù. ÇöÀç ȯÀÚ¿¡°Ô Áõ»óÀÌ ÀÖÀ¸¹Ç·Î ´Ù¸¥ ¾àÀ¸·Î ±³Ã¼ÇÏ°Ú½À´Ï´Ù.
[2014-9-25. ÀÌÁØÇà ÀÇ°ß]
³»½Ã°æ ¼Ò°ßÀº ¾Öµ¶ÀÚ 3ÀÇ ¸»¾¸Ã³·³ multiple raised erosions and flat erosions µéÀÔ´Ï´Ù. ¶Ñ·ÇÇÏ°Ô ±Ë¾çÀ̶ó°í ¸»ÇÒ ¼ö ÀÖ´Â ºÎºÐÀº ¾ø½À´Ï´Ù. Àú´Â ±Ë¾çÀÌ ¾Æ´Ñ °ÍÀ» ±Ë¾çÀ¸·Î ºÎ¸£Áö ¸»±â¸¦ ±ÇÇÕ´Ï´Ù. º¸Çè ±ÔÁ¤»ó ¾î¿ ¼ö ¾øÀÌ ±Ë¾çÀ» ºÎ¸£´Â °æ¿ì°¡ ÀÖ´Ù´Â °ÍÀ» Àß ¾ËÁö¸¸ ±ÇÇÒ »çÇ×Àº ¾Æ´Õ´Ï´Ù.
NSAID¿¡ ÀÇÇÑ dyspepsia·Î º¼ ¼ö ÀÖ°Ú½À´Ï´Ù. ¾àÀ» ²÷À¸¸é ÁÁÁö¸¸ ²÷À» ¼ö ¾øÀ¸¸é ¾Æ·¡ Á¦½ÃÇÑ °¡À̵å¶óÀο¡ µû¶ó H2RA ȤÀº PPI¸¦ ½á º¸´Â °ÍÀÌ ¼ø¼ÀÏ °Í °°½À´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼´Â º¸Çè°ü·Ã À̽´¶§¹®¿¡ PPI¸¦ ¾²°í ½Í¾îµµ Çö½ÇÀûÀÎ Á¦¾àÀÌ Å®´Ï´Ù. ±×·¡¼ Àú´Â ranitidineÀ̳ª famotidineÀ» µå¸³´Ï´Ù. CimetidineÀº Á¶±Ý ¾àÇÑ °Í °°¾Æ¼ °ÅÀÇ »ç¿ëÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. RanitidineÀ̳ª famotidineÀ¸·Î È¿°ú°¡ ¾øÀ¸¸é ÀÌ¿¡ ´ëÇÏ¿© Àǹ«±â·ÏÀ» ³²±ä ÈÄ PPI·Î º¯°æÇÏ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã´Ù½ÃÇÇ ÀÌ·± setting¿¡¼ prokinetics´Â °ÅÀÇ È¿°ú°¡ ¾ø¾î¼ »ç¿ëÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. Mucoprotective agents°¡ µµ¿òµÈ´Ù´Â ¸Å¿ì ¹Ì¾àÇÑ ±Ù°Å°¡ ÀÖ½À´Ï´Ù¸¸ ¹Ï°í ¾µ Á¤µµ´Â ¾Æ´Ï¶ó°í »ý°¢ÇϹǷΠ»ç¿ëÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. À§»êºÐºñ¾ïÁ¦Á¦¸¦ Åõ¿©ÇÏ´Â »óȲ¿¡¼ antacid´Â PRNÀ¸·Î¸¸ ó¹æÇÕ´Ï´Ù. Á¤±Ôó¹æÀ¸·Î ÇÔ²² ¾µ »óȲÀº ¾Æ´Ï¶ó°í »ý°¢ÇÕ´Ï´Ù.
¿ì¸®³ª¶ó º¸Çè±ÔÁ¤°ú ¹«°üÇÏ°Ô ÀÇ»ç ¼Ò½Å²¯ Áø·áÇÏ´Â »óȲÀ̶ó¸é À̾߱â´Â ´Þ¶óÁý´Ï´Ù. Helicobacter °¡ ÀÖÀ¸¸é Á¦±ÕÄ¡·á¸¦ ÇÕ´Ï´Ù (Áõ»óÀÌ ÁÁ¾ÆÁø´Ù´Â ¼³µµ ÀÖ°í ÃÖ¼ÒÇÑ aspirin¿¡ ÀÇÇÑ ulcer bleedingÀº »ó´çºÎºÐ ¿¹¹æµË´Ï´Ù). ±×·¡µµ Áõ»óÀÌ ÀÖÀ¸¸é óÀ½ºÎÅÍ PPI¸¦ ¾¹´Ï´Ù. ±×·¡µµ Áõ»óÀÌ ÀÖÀ¸¸é aspirinÀ» ´Ù¸¥ antiplateletÀ¸·Î º¯°æÇÕ´Ï´Ù (´Ù¸¥ °Í¿¡ ¾Õ¼ ¾à º¯°æÀ» ¸ÕÀú Çغ¸´Â °Íµµ °¡´ÉÇÕ´Ï´Ù). ÇöÀç ¿ì¸®³ª¶ó¿¡¼ ÀÌ·¸°Ô ÇÏ¸é ¹Ù·Î »è°¨´çÇÕ´Ï´Ù. µû¶ó¼ ¸¹Àº ºÐµéÀÌ "±Ë¾ç"À¸·Î °úÀ×Áø´ÜÀ» ÇÏ´Â °ÍÀÔ´Ï´Ù.
[2010. ¾Öµ¶ÀÚ Áú¹®]
³»¿ø 10ÀÏÀüºÎÅÍ ¹ß»ýÇÑ epigastric soreness ÀÖ¾î¼ ³»¿øÇÏ¿´°í, ³»½Ã°æ»ó fundus ¿¡¼ antrum °ÉÄ£ À§ Àüü¿¡¼, central erosion °ú exudate ¸¦ °¡Áø hyperemic round elevated lesion ÀÌ °üÂûµÇ¾ú½À´Ï´Ù. angle, LB, MB ¿¡ ÀÖ´Â º´º¯¿¡¼ Á¶Á÷ °Ë»ç¸¦ ½ÃÇàÇÏ¿´°í, Á¶Á÷ °Ë»ç °á°ú ´ÙÀ½°ú °°½À´Ï´Ù.
1. Stomach, angle, biopsy:Chronic gastritis, active, with intestinal metaplasia (incomplete type) and lymphoid aggregate. No H. pylori identified.
2. Stomach, low body, anterior, biopsy: Chronic gastritis, active, No H. pylori identified.
3. Stomach, mid body, greater curvature, biopsy: Chronic gastritis, active, No H. pylori identified.
Angle Á¶Á÷ °Ë»ç °á°úÀÎ lymphoid aggregates ´Â Àǹ̰¡ ÀÖ´Â °ÍÀÎÁö, ±×¸®°í assess °¡ ¹«¾ùÀÎÁö¿ä. ¶ÇÇÑ ¿Ü·¡¿¡ ³»¿øÇÒ È¯ÀÚÀε¥, ÃßÈÄ F/U ¹× Ä¡·á´Â ¾î¶»°Ô ÇØ¾ß ÇÏ´ÂÁö¿ä.
[2010. ÀÌÁØÇà ´äº¯]
Erosive gastritis·Î º¸¸é ¾î¶»°Ú½À´Ï±î. »ç½Ç 3³â Àü ½ÊÀÌÁöÀå ÃâÇ÷·Î ³»¿øÇÏ¿´À» ´ç½Ã »çÁø¿¡µµ À§ erosionÀÌ ÀÖ¾ú½À´Ï´Ù. Áõ»ó¿¡ ´ëÇÑ ¾àÀ» Á¶±Ý µå¸®°í È£ÀüµÇ¸é »óȲÀ» Á¾·áÇÏ°í 1³â ÈÄ ³»½Ã°æÇÏ¸é µÇ°Ú´Ù°í »ý°¢µÇ¾ú½À´Ï´Ù. ¿µ °ÆÁ¤µÇ¸é ¹Ý³â ÈÄ.
ÀÌ·± °æ¿ì¿¡ lymphoid aggregate´Â Å« Àǹ̰¡ ¾ø½À´Ï´Ù. ³»½Ã°æ À°¾È¼Ò°ß¿¡¼ lymphoma °è¿ÀÌ ÀǽɵǴ °æ¿ì¿¡´Â ¾î´À Á¤µµ Àǹ̸¦ ºÎ¿©ÇÒ ¼ö ÀÖÁö¸¸ ±× ÀÌ¿Ü¿¡´Â Á߿伺À» ºÎ¿©ÇÏÁö ¾Ê´Â °ÍÀÌ ³´´Ù°í º¾´Ï´Ù.
[2014-9-23. ¾Öµ¶ÀÚ Áú¹®]
¼±»ý´Ô ±ÛÀ» º¸¸é¼ ¸¹Àº µµ¿òÀ» ¹Þ°í ÀÖ´Â ¾Öµ¶ÀÚ(?) ÀÔ´Ï´Ù. ¼±»ý´ÔÀÇ Áø·á¿¡ ´ëÇÑ Ã¶Çп¡ ¸¹Àº ºÎºÐ °ø°¨ÇÏ¸ç »ý°¢µµ ¸¹ÀÌ ÇÏ°í ÀÖ½À´Ï´Ù. °ËÁø³»½Ã°æÀ» ÇÏ´Ù°¡ ±Ã±ÝÇÑ Á¡ÀÌ ÀÖ¾î Áú¹®µå¸³´Ï´Ù.
¹Ì¶õ°ú ±Ë¾çÀº ±íÀÌ¿¡ µû¶ó Á¤ÀÇÇÏ°í ÀÖ½À´Ï´Ù. ±×·±µ¥ ¸·»ó ³»½Ã°æ¿¡¼ ÀÌ·± ±¸ºÐÀÌ ¾Ö¸ÅÇÑ °æ¿ì°¡ ÀÖ½À´Ï´Ù. Å©±â°¡ ¾ÆÁÖ Å« ¹Ì¶õÀÌ ±Ë¾çó·³ º¸À̱⵵, Å©±â°¡ ÀÛÀº ±Ë¾çÀÌ ¹Ì¶õó·³ º¸À̱⵵ ÇÕ´Ï´Ù. °¡²û È¥¶õ½º·¯¿ï ¶§°¡ ÀÖ½À´Ï´Ù. µÎ º´º¯ ±¸º°ÀÌ ±íÀÌ¿¡ µû¶ó Á¤ÇØÁö´Â °ÍÀ̹ǷΠ±íÀÌ¿¡ ´ëÇÑ ¾î¶² Áõ°Åµé, ¿¹¸¦µé¾î ÁÖº¯ ÁÖ¸§ÀÇ ÁýÁߵǴ ¾ç»óÀ̳ª Á¶Á÷°Ë»ç½Ã °æµµ °°Àº °Í»Ó¸¸ ¾Æ´Ï¶ó ¿©·¯°¡Áö Ư¡ÀÌ ´Ù¸¦ °Í °°Àºµ¥ ¸·»ó ±¸º°ÀÌ ¾î·Á½À´Ï´Ù. Á¤È®ÇÏ°Ô µü Àß¶ó¼ ±¸º°ÇÒ ¼ö ¾ø´Â °æ¿ì ¹Ì¶õ°ú ±Ë¾çÀº Ä¡·á°¡ ´Ù¸£±â¿¡ ±¸º°ÀÌ Áß¿äÇÏ´Ù°í »ý°¢Çϴµ¥¿ä...
¾Ç¼º°úÀÇ °¨º°¿¡ ´ëÇÑ ³»¿ëÀº Çлý¶§ºÎÅÍ Á·º¸À̱⵵ ÇÏ°í Ã¥¿¡µµ ÀÚÁÖ ´Ù·ïÁö±â¿¡ ½±Áö´Â ¾ÊÀ¸³ª Ư¡µéÀ» ãÀ¸¸é µÇ´Â°Å °°Àºµ¥... ¹Ì¶õ°ú ±Ë¾çÀÇ ±¸º°¿¡ ´ëÇÑ ³»¿ëÀº Àß Ã£±â°¡ ¾î·Æ½À´Ï´Ù. ±Ë¾çÀÎ °æ¿ì Ç︮ÄÚ ¹ÚÅÍ °Ë»ç³ª Á¦±ÕÄ¡·á¸¦ °í·ÁÇØ¾ß ÇÏ´Â °ÍÀÌ ¿øÄ¢ÀÌ°í ¹«Áõ»ó ¹Ì¶õÀ̶ó¸é ÀÏ´Ü ÁöÄѺÁ¾ß ÇÒÅ״ϱî¿ä. Ȥ½Ã ¼±»ý´ÔÀÌ »ç¿ëÇϽô ÀÌ µÑÀÇ ±¸ºÐ¹æ¹ýÀÌ ÀÖÀ»±î¿ä?
°¡²û ¹Ì¶õ°ú ±Ë¾çÀ» ±¸º°ÇÏÁö ¸øÇÏ´Â »ç¶÷µéÀÌ ÀÖ´Ù´Â ¸»À» µè´Âµ¥.... Àúµµ ±×Áß¿¡ ÇϳªÀÎ°Í °°¾Æ ´ä´äÇÕ´Ï´Ù. Çϸé ÇÒ¼ö·Ï ³»½Ã°æÀº ¾î·Æ³×¿ä^^ Ã¥ÀÓ°¨µµ ¸¹ÀÌ ´À²¸Áö±¸¿ä. ¾Æ´Â °ÍÀÌ ¸¹À»¼ö·Ï °í¹Îµµ ¸¹¾ÆÁö´Â µí ÇÕ´Ï´Ù.
[2014-9-24. ÀÌÁØÇà ´äº¯]
ÁÁÀº Áú¹® °¨»çÇÕ´Ï´Ù. ±Ë¾ç°ú ¹Ì¶õÀ» ±¸ºÐÇÏÁö ¸øÇÏ´Â »ç¶÷ÀÌ ¸¹Àº °ÍÀº ¾Æ´Õ´Ï´Ù. ¹Ì¶õÀ» ±Ë¾çÀ̶ó°í ºÙÀÌ´Â °æ¿ì°¡ ¸¹´Ù°í º¸´Â °ÍÀÌ ¿Ç°Ú½À´Ï´Ù. Æí¸®Çϱ⠶§¹®ÀÌÁö¿ä. ±×·±µ¥ Àǻ翡°Ô¸¸ Æí¸®ÇÕ´Ï´Ù. ȯÀÚ¿¡°Ô´Â Æí¸®ÇÏÁö ¾Ê½À´Ï´Ù. À̹ø ±âȸ¿¡ »ó¼¼È÷ ³íÀÇÇØ º¸°Ú½À´Ï´Ù.
[2020-9-10. YouTube Áú¹®]
´Ü¹ß¼º ¹Ì¶õ Á¶Á÷°Ë»ç¸¦ Çߴµ¥¿ä ¾Ï È®·üÀÌ ¸¹ÀÌ ³ô¾Æ¼ Çϴ°ǰ¡¿ä? ¼±»ý´ÔÀº ¾Æ´Ò°Å¶ó´Âµ¥ Ȥ½Ã³ªÇؼ Á¶Á÷°Ë»ç ÇѰŶó´Âµ¥¿ä ȯÀÚÀÎ Á¦°¡ ºÒ¾ÈÇÒ±îºÁ °á°úÀü±îÁö ¾Æ´Ò°Å¶ó°í ÇØÁֽô°ÇÁö ³Ê¹« ºÒ¾ÈÇÕ´Ï´Ù.
[2020-9-10. ÀÌÁØÇà ´äº¯]
´ÜÀÏ ¹Ì¶õÀº ÃÖÁ¾ Áø´ÜÀ» ¿¹ÃøÇϱ⠾î·Á¿î °æ¿ì·Î Á¶Á÷°Ë»ç¸¦ ±â´Ù¸®´Â ¼ö ¹Û¿¡ ´Ù¸¥ ¹æ¹ýÀÌ ¾ø´Â Á¾·ùÀÔ´Ï´Ù. À°¾È ¿¹ÃøÀÇ Á¤È®µµ°¡ ³·¾Æ¼ Çö¹Ì°æÀ¸·Î °üÂûÇÑ º´¸®°á°ú¸¦ º¸°í ¹æħÀ» Á¤ÇÏ°í ÀÖ½À´Ï´Ù. ´ÜÀÏ ¹Ì¶õ Áß ³ª»Û °á°ú°¡ ³ª¿À´Â °æ¿ì´Â º¸Åë 10% ¹Ì¸¸À¸·Î ÃßÁ¤ÇÏ°í ÀÖ½À´Ï´Ù.
2) ¸¸¼º À§¿°ÀÇ ³»½Ã°æÀû Áø´Ü¿¡ ´ëÇÑ Á¶»ç (2014. Survey ³í¹®)
3) EndoTODAY ¹Ì¶õ¼º À§¿° Erosive gastritis
4) EndoTODAY Lymphofollicular gastritis¿¡ ´ëÇÑ Åä·Ð
5) Atrophy & metaplastia º´º¯ÀÇ ÃßÀû°ü¸® (2009. ³»½Ã°æ¼¼¹Ì³ª °ÀÇÀÚ·á)
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.